Sort
85,873 grants matching “alzheimers”
Impact of Amyloid and Tau on the Aging Brain: The Harvard Aging Brain Study
$2,689,773Reisa A. Sperling · Massachusetts General Hospital · P01 · FY2019 · AG
Soluble αSyn is a modulator of AD pathophysiology
$2,689,594Sylvain E. Lesne · University Of Minnesota · RF1 · FY2019 · AG
ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE
$2,688,971Reisa A. Sperling · University Of California, San Diego · U19 · FY2017 · AG
Defining the cell-specific epigenetic landscape leading to altered gene expression signatures in HIV-Associated Neurocognitive Disorder
$2,688,892Christopher K Glass · University Of California, San Diego · RF1 · FY2018 · AG
Siemens Eclipse HP Cyclotron for PET Imaging Research
$2,688,777Chester A Mathis · University Of Pittsburgh At Pittsburgh · S10 · FY2010 · RR
Multicultural Community Dementia Screening
$2,687,896James E Galvin · University Of Miami School Of Medicine · R01 · FY2023 · AG
Cellular mechanisms of neuronal dysfunction in addiction and neurodegeneration
$2,685,245Brandon Harvey · National Institute On Drug Abuse · ZIA · FY2025 · DA
Establishment of a Human Microphysiological System to Elucidate Cellular Mechanisms Underlying Vulnerability to AD
$2,683,965Tracy L Young-Pearse · Brigham And Women'S Hospital · RF1 · FY2025 · NS
GLASS-AD: Global Latinos Sequencing Study for Alzheimer's Disease
$2,682,382Giuseppe Tosto · Columbia University Health Sciences · U01 · FY2024 · AG
Center for Alzheimer's and Related Dementias (CARD): Long-read DNA sequencing of Alzheimers Disease and Related Dementias cases
$2,681,627Mark Cookson · National Institute On Aging · ZIA · FY2025 · AG
FUNCTIONAL AND HEALTH CHANGES OF THE ELDERLY
$2,681,136Duke University · R01 · FY2001 · AG
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
$2,680,709Michael G Agadjanyan · Institute For Molecular Medicine · R01 · FY2022 · AG
Neural mechanism of spatial navigation and memory
$2,680,599Yi Gu · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS
Alzheimer's Disease Research Center
$2,679,551Douglas R Galasko · University Of California, San Diego · P50 · FY2007 · AG
Late-onset Unexplained Epilepsy as a Risk Factor for Dementia
$2,677,018Alice D Lam · Massachusetts General Hospital · R01 · FY2025 · NS
Presenilin and APP in the Brain
$2,675,675Jie Shen · Brigham And Women'S Hospital · RF1 · FY2021 · NS
Relationship Between Neural Correlates of Episodic Memory,Age, Memory Performance
$2,674,253Michael D Rugg · University Of Texas Dallas · RF1 · FY2017 · AG
Brain-wide screen for a neural pacemaker of aging
$2,673,450Karl Alexander Deisseroth · Stanford University · R01 · FY2020 · AG
Mild Cognitive Impairment: A Prospective Community Study
$2,671,320Mary Ganguli · University Of Pittsburgh At Pittsburgh · R37 · FY2025 · AG
Slide-seq: high-resolution in situ expression profiling for neuropathology
$2,670,000Evan Z Macosko · Broad Institute, Inc. · DP2 · FY2017 · AG
Pink1, amyloid pathology, and mitchondrial quality control in Alzheimer's Disease
$2,667,200Shi Du Yan · Columbia University Health Sciences · RF1 · FY2018 · AG
RNA dynamics and co-translational decay in aging and aging-related disease
$2,665,909Emmanouil Maragkakis · National Institute On Aging · ZIA · FY2021 · AG
DISCOVERY - Repository Core
$2,665,146Karl Gerard Helmer · Massachusetts General Hospital · U19 · FY2024 · NS
Pediatric Brain Imaging
$2,664,586Jay N Giedd · National Institute Of Mental Health · ZIA · FY2009 · MH
Mechanisms Of Synaptic Plasticity In The Adult And Developing Nervous System
$2,663,604Serena M Dudek · National Institute Of Environmental Health Sciences · ZIA · FY2014 · ES